K Noftall1,2, M Taylor1, L Hoang3,4, E Galanis1,2. 1. BC Centre for Disease Control, Vancouver, BC. 2. School of Population and Public Health, University of British Columbia, Vancouver, BC. 3. BC Centre for Disease Control Public Health Laboratory, Vancouver, BC. 4. Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC.
Abstract
BACKGROUND: Shiga toxin-producing Escherichia coli (STEC) can cause severe illness including bloody diarrhea and hemolytic-uremic syndrome (HUS) through the production of Shiga toxins 1 (Stx1) and 2 (Stx2). E. coli O157:H7 was the most common serotype detected in the 1980s to 1990s, but improvements in laboratory methods have led to increased detection of non-O157 STEC. Non-O157 STEC producing only Stx1 tend to cause milder clinical illness. Exclusion guidelines restrict return to high-risk work or settings for STEC cases, but most do not differentiate between STEC serogroups and Stx type. OBJECTIVE: To analyze British Columbia (BC) laboratory and surveillance data to inform the BC STEC exclusion guideline. METHODS: For all STEC cases reported in BC in 2011-2017, laboratory and epidemiological data were obtained through provincial laboratory and reportable disease electronic systems, respectively. Incidence was measured for all STEC combined as well as by serogroup. Associations were measured between serogroups, Stx types and clinical outcomes. RESULTS: Over the seven year period, 984 cases of STEC were reported. A decrease in O157 incidence was observed, while non-O157 rates increased. The O157 serogroup was significantly associated with Stx2. Significant associations were observed between Stx2 and bloody diarrhea, hospitalization and HUS. CONCLUSION: The epidemiology of STEC has changed in BC as laboratories increasingly distinguish between O157 and non-O157 cases and identify Stx type. It appears that non-O157 cases with Stx1 are less severe than O157 cases with Stx2. The BC STEC exclusion guidelines were updated as a result of this analysis.
BACKGROUND: Shiga toxin-producing Escherichia coli (STEC) can cause severe illness including bloody diarrhea and hemolytic-uremic syndrome (HUS) through the production of Shiga toxins 1 (Stx1) and 2 (Stx2). E. coli O157:H7 was the most common serotype detected in the 1980s to 1990s, but improvements in laboratory methods have led to increased detection of non-O157 STEC. Non-O157 STEC producing only Stx1 tend to cause milder clinical illness. Exclusion guidelines restrict return to high-risk work or settings for STEC cases, but most do not differentiate between STEC serogroups and Stx type. OBJECTIVE: To analyze British Columbia (BC) laboratory and surveillance data to inform the BC STEC exclusion guideline. METHODS: For all STEC cases reported in BC in 2011-2017, laboratory and epidemiological data were obtained through provincial laboratory and reportable disease electronic systems, respectively. Incidence was measured for all STEC combined as well as by serogroup. Associations were measured between serogroups, Stx types and clinical outcomes. RESULTS: Over the seven year period, 984 cases of STEC were reported. A decrease in O157 incidence was observed, while non-O157 rates increased. The O157 serogroup was significantly associated with Stx2. Significant associations were observed between Stx2 and bloody diarrhea, hospitalization and HUS. CONCLUSION: The epidemiology of STEC has changed in BC as laboratories increasingly distinguish between O157 and non-O157 cases and identify Stx type. It appears that non-O157 cases with Stx1 are less severe than O157 cases with Stx2. The BC STEC exclusion guidelines were updated as a result of this analysis.
Authors: D Werber; A Fruth; U Buchholz; R Prager; M H Kramer; A Ammon; H Tschäpe Journal: Eur J Clin Microbiol Infect Dis Date: 2003-11-12 Impact factor: 3.267
Authors: Martina Bielaszewska; Alexander W Friedrich; Thomas Aldick; Robin Schürk-Bulgrin; Helge Karch Journal: Clin Infect Dis Date: 2006-10-02 Impact factor: 9.079
Authors: L W Riley; R S Remis; S D Helgerson; H B McGee; J G Wells; B R Davis; R J Hebert; E S Olcott; L M Johnson; N T Hargrett; P A Blake; M L Cohen Journal: N Engl J Med Date: 1983-03-24 Impact factor: 91.245
Authors: Josefa M Rangel; Phyllis H Sparling; Collen Crowe; Patricia M Griffin; David L Swerdlow Journal: Emerg Infect Dis Date: 2005-04 Impact factor: 6.883
Authors: Lin T Brandal; Astrid L Wester; Heidi Lange; Inger Løbersli; Bjørn-Arne Lindstedt; Line Vold; Georg Kapperud Journal: BMC Infect Dis Date: 2015-08-11 Impact factor: 3.090